Show simple item record

dc.contributor.authorBrumovsky, Pablo.
dc.contributor.authorVillar, Marcelo.
dc.contributor.authorTate, Pablo.
dc.contributor.authorEt al.
dc.date.accessioned2023-09-11T18:34:15Z
dc.date.available2023-09-11T18:34:15Z
dc.date.issued2021-09
dc.identifier.citationJ Neuroimmune Pharmacol . 2021 Sep;16(3):651-666.es
dc.identifier.issn1557-1904
dc.identifier.urihttps://riu.austral.edu.ar/handle/123456789/2286
dc.descriptionDisponible en: https://link.springer.com/article/10.1007/s11481-020-09971-2es
dc.description.abstractAbstract IMT504 is a non-CPG, non-coding synthetic oligodeoxinucleotide (ODN) with immunomodulatory properties and a novel inhibitory role in pain transmission, exerting long-lasting analgesic effects upon multiple systemic administrations. However, its mechanisms of anti-nociceptive action are still poorly understood. In the present study in male adult rats undergoing complete Freund's adjuvant-induced hindpaw inflammation, we focused in the analysis of the immunomodulatory role of IMT504 over the cellular infiltrate, the impact on the inflammatory milieu, and the correlation with its anti-allodynic role. By means of behavioral analysis, we determined that a single subcutaneous administration of 6 mg/kg of IMT504 is sufficient to exert a 6-week-long full reversal of mechanical and cold allodynia, compromising neither acute pain perception nor locomotor activity. Importantly, we found that the anti-nociceptive effects of systemic IMT504, plus quick reductions in hindpaw edema, were associated with a modulatory action upon cellular infiltrate of B-cells, macrophages and CD8+ T-cells populations. Accordingly, we observed a profound downregulation of several inflammatory leukocyte adhesion proteins, chemokines and cytokines, as well as of β-endorphin and an increase in the anti-inflammatory cytokine, interleukin-10. Altogether, we demonstrate that at least part of the anti-nociceptive actions of IMT504 relate to the modulation of the peripheral immune system at the site of injury, favoring a switch from pro- to anti-inflammatory conditions, and provide further support to its use against chronic inflammatory pain. Graphical abstract GA short description - IMT504 systemic Administration. Systemic administration of the non-CpG ODN IMT504 results in a 6-week long blockade of pain-like behavior in association with anti-inflammatory responses at the site of injury. These include modulation of lymphoid and myeloid populations plus downregulated expression levels of multiple pro-inflammatory cytokines and β-endorphin. Nocifensive responses and locomotion remain unaltered. Keywords: Complete Freund’s adjuvant (CFA); Cytokines; IMT504; Lymphocytes; Oligonucleotide; Pain. © 2020. Springer Science+Business Media, LLC, part of Springer Nature.es
dc.language.isoenes
dc.publisherSpringer [Commercial Publisher]es
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectComplete Freund’s adjuvant (CFA).es
dc.subjectCytokines.es
dc.subjectIMT504.es
dc.titleIMT504 Provides Analgesia by Modulating Cell Infiltrate and Inflammatory Milieu in a Chronic Pain Modeles
dc.typeArticlees


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internacional